Insights

Innovative Vaccine Platforms HDT Bio is actively developing next-generation vaccine and immunotherapy technologies, including RNA and saRNA platforms, with ongoing collaborations and substantial government funding, indicating strong potential for partnership and licensing opportunities in advanced vaccine development.

Expanding Therapeutic Pipeline The company's focus on broad indications such as cancer and infectious diseases, combined with their proprietary platforms like LION and PROVIDENT, presents multiple opportunities to introduce complementary products or expand into new markets through strategic alliances.

Funding and Growth Momentum Recent awards totaling over $1.75 million and ongoing government contracts highlight the company's active funding environment, making it a promising partner for joint ventures, research collaborations, and co-development initiatives.

Market Focus and Trends HDT Bio’s emphasis on rapid and adaptable RNA vaccine technologies aligns with current market trends toward quick response platforms for emerging viral threats, opening avenues for sales of research equipment, laboratory services, or integrated vaccine solutions.

Employee and Partnership Strengths With a dedicated team of up to 200 employees and regional manufacturing and clinical collaborations, HDT Bio is positioned as a reliable partner capable of scaling innovative biotech products, ideal for establishing supply agreements, licensing deals, or distribution networks.

HDT Bio Tech Stack

HDT Bio uses 8 technology products and services including Site Kit, WordPress, Squarespace, and more. Explore HDT Bio's tech stack below.

  • Site Kit
    Analytics
  • WordPress
    Content Management System
  • Squarespace
    Content Management System
  • Open Graph
    Content Management System
  • MySQL
    Database
  • Slick
    Javascript Libraries
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines

Media & News

HDT Bio's Email Address Formats

HDT Bio uses at least 1 format(s):
HDT Bio Email FormatsExamplePercentage
First.Last@hdt.bioJohn.Doe@hdt.bio
50%
First.Last@hdt.bioJohn.Doe@hdt.bio
50%

Frequently Asked Questions

What is HDT Bio's official website and social media links?

Minus sign iconPlus sign icon
HDT Bio's official website is hdt.bio and has social profiles on LinkedInCrunchbase.

What is HDT Bio's SIC code NAICS code?

Minus sign iconPlus sign icon
HDT Bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does HDT Bio have currently?

Minus sign iconPlus sign icon
As of December 2025, HDT Bio has approximately 60 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Director Of Virology: J. E.Clinical Trial Manager: J. K.Data Manager: S. R.. Explore HDT Bio's employee directory with LeadIQ.

What industry does HDT Bio belong to?

Minus sign iconPlus sign icon
HDT Bio operates in the Biotechnology Research industry.

What technology does HDT Bio use?

Minus sign iconPlus sign icon
HDT Bio's tech stack includes Site KitWordPressSquarespaceOpen GraphMySQLSlickPHPYoast SEO.

What is HDT Bio's email format?

Minus sign iconPlus sign icon
HDT Bio's email format typically follows the pattern of First.Last@hdt.bio. Find more HDT Bio email formats with LeadIQ.

How much funding has HDT Bio raised to date?

Minus sign iconPlus sign icon
As of December 2025, HDT Bio has raised $9M in funding. The last funding round occurred on Feb 16, 2021 for $3M.

When was HDT Bio founded?

Minus sign iconPlus sign icon
HDT Bio was founded in 2018.

HDT Bio

Biotechnology ResearchWashington, United States51-200 Employees

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. 

HDT Bio offers a comprehensive compensation plan, which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week-long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. 

HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce.

Section iconCompany Overview

Website
hdt.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
51-200

Section iconFunding & Financials

  • $9M

    HDT Bio has raised a total of $9M of funding over 2 rounds. Their latest funding round was raised on Feb 16, 2021 in the amount of $3Mas a seed.

  • $25M$50M

    HDT Bio's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $9M

    HDT Bio has raised a total of $9M of funding over 2 rounds. Their latest funding round was raised on Feb 16, 2021 in the amount of $3Mas a seed.

  • $25M$50M

    HDT Bio's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.